Trials / Completed
CompletedNCT04261517
Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Shanghai Public Health Clinical Center · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.
Detailed description
There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments |
Timeline
- Start date
- 2020-02-06
- Primary completion
- 2020-02-25
- Completion
- 2020-02-25
- First posted
- 2020-02-07
- Last updated
- 2020-04-13
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04261517. Inclusion in this directory is not an endorsement.